Abstract 2200P
Background
Mediastinal neoplasms are typical but uncommon thoracic diseases with increasing incidence and unfavorable prognoses. A comprehensive understanding of their spatiotemporal distribution is essential for accurate diagnosis and timely treatment. However, previous studies are limited in scale and data coverage. Therefore, we delineate the distribution of mediastinal lesions within a substantial, nationwide, multi-institutional cohort, thereby providing valuable insights into this disease.
Methods
In this multi-center, hospital-based, observational study, we included 20 hospitals from 11 provinces in China. At each institution, a standardized retrospective search of electronic medical records between Jan. 1st, 2009 and Dec. 31st, 2020 was performed. We collected information on sociodemographic characteristics, CT images, and pathologic diagnoses. The incidence of mediastinal neoplasms was analyzed in terms of age, sex, time, compartment, and geographical region.
Results
Among 7,829 cases, the most common mediastinal lesions were thymomas (30.6%), benign mediastinal cysts (23.3%), and neurogenic tumors (10.0%). The distribution of these lesions varied significantly among mediastinal compartments, with thymomas (39.6%), benign cysts (28.0%), and neurogenic tumors (51.7%) being the most commonly observed lesions in the prevascular, visceral, and paravertebral mediastinum, respectively (P < 0.001). The occurrence of mediastinal lesions varied by age, with germ cell tumors being more frequently observed in patients younger than 18 and those aged 18-29 years, whereas thymomas occurred more often in patients over 30 (P < 0.001). Also, the lesion location was associated with age, with patients having paravertebral lesions being the youngest (P < 0.001). Spatial distribution analysis revealed that thymomas were the most common mediastinal lesions across different geographical regions.
Conclusions
This study revealed significant heterogeneity in the spatiotemporal distribution of mediastinal neoplasms. These findings provide useful demographic data when considering the differential diagnosis of mediastinal lesions, and would be beneficial for tailoring disease prevention and control strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2183P - The relevance of HFpEF in immunotherapy-induced myocarditis: An analysis of 65 patients
Presenter: Adam Chapman
Session: Poster session 07
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07